Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.
Contribution to Group revenue (%)
Revenue by segment (%)
- The Japanese pharmaceutical sector continues to be negatively impacted by regulated price revisions and was valued at USD76 billion as at 31 December 2018
Source: December 2018 IQVIA
Number of products launched:
In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
# The number of product launches has been restated to take into account discontinued operations.
|Total||2 124||2 119||0|
|Sterile Focus Brands||1 364||1 384||(1)|
|Anaesthetics Brands||1 332||1 331||0|
Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.